Long-lasting spray disinfectant achieving 99.999% pathogen reduction within 10 minutes and 90+ days of residual efficacy

Overview

This solution is a long-lasting spray disinfectant designed to rapidly eliminate bacteria and viruses on contact while maintaining residual antimicrobial and antiviral activity for an extended period. The formulation achieves a 3-5 log reduction (99.9-99.999%) in pathogen levels within 10 minutes of application and continues to deliver sustained kill performance at the same level for 90+ days post-application. It has been tested against a broad range of pathogens, including Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella enterica, hCoV-229E, and SARS-CoV-2.

The product is non-toxic, food-safe, and non-carcinogenic/mutagenic, making it suitable for use in environments where safety and regulatory compliance are critical. It addresses the heightened consumer and institutional demand for disinfectants that go beyond one-time cleaning to provide ongoing surface protection, particularly in the wake of COVID-19.

Technical specifications

Key features and performance:

• Achieves 3-5 log (99.9-99.999%) microbial reduction within 10 minutes of contact
• Demonstrates up to 7 log reduction for certain bacteria after 30 minutes
• Maintains residual kill efficacy at 3-5 log levels for 90+ days after a single application
• Validated against bacterial pathogens (Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella enterica) and viral pathogens (hCoV-229E, SARS-CoV-2)
• Non-toxic, food-safe, and non-carcinogenic/mutagenic formulation

Testing and validation standards:

• Tested in accordance with JIS Z 2801 and ISO 22196 industry standards for antimicrobial surface efficacy
• External third-party validation conducted by EMSL Analytical Labs
• Internal laboratory data supports 90+ day residual efficacy claims

Technology readiness level

The disinfectant has completed internal laboratory validation and independent third-party testing through EMSL Analytical Labs, confirming rapid kill and residual performance claims across multiple pathogen categories. The next phase involves regulatory approval, with plans to pursue EPA and Health Canada registration under their newly established pathways for residual disinfectants. Additional pathogen testing is planned to expand the range of kill claims supported by the product. The technology is positioned for commercialization following regulatory clearance, with demonstrated efficacy supporting near-term deployment in target markets.